The pathogenesis of COVID-19 appears to be characterized by a dysregulated immune response. During the first pandemic wave in Lombardy, we started to administer glucocorticoids to some patients with severe respiratory failure requiring support with Continuous Positive Airway Pressure (CPAP) therapy. We retrospectively collected data to identify the effect of glucocorticoids in this COVID-19 particular population. With a multidisciplinary consensus, we administered to selected patients with severe COVID-19 disease (PaO2/FiO2 159±71 mmHg) 0,91 mg/kg/die of methylprednisolone equivalent dose after a median of 8 days of hospitalization. In our study we compared 57 patients from the steroid group with 123 from the control group: the event of invasive mechanical ventilation or death was reduced by 43% between steroid group and control group (19.3 % vs. 34.1 % respectively, p=0.001) and mortality was reduced by about 31% between steroid and usual care alone (15.8 % vs. 22.8 % respectively, p=0.011). Corticosteroids in selected COVID-19 patients may have a relevant impact on outcome, better profiling of the heterogeneity of this disease may be essential to guarantee the best treatment choices.

Vergnano, B., Calcinati, S., Signori, D., Benini, A., Pozzi, M., Verga, L., et al. (2021). Steroids in severe COVID-19 patients: A retrospective analysis on the first pandemics in Lombardy. EMERGENCY CARE JOURNAL, 17(3) [10.4081/ecj.2021.9888].

Steroids in severe COVID-19 patients: A retrospective analysis on the first pandemics in Lombardy

Vergnano, Beatrice;Calcinati, Serena;Signori, Davide
;
Benini, Annalisa;Pozzi, Maria Rosa;Verga, Luisa;Pizzagalli, Jonata;Bonfanti, Paolo;Bellani, Giacomo;Foti, Giuseppe
2021

Abstract

The pathogenesis of COVID-19 appears to be characterized by a dysregulated immune response. During the first pandemic wave in Lombardy, we started to administer glucocorticoids to some patients with severe respiratory failure requiring support with Continuous Positive Airway Pressure (CPAP) therapy. We retrospectively collected data to identify the effect of glucocorticoids in this COVID-19 particular population. With a multidisciplinary consensus, we administered to selected patients with severe COVID-19 disease (PaO2/FiO2 159±71 mmHg) 0,91 mg/kg/die of methylprednisolone equivalent dose after a median of 8 days of hospitalization. In our study we compared 57 patients from the steroid group with 123 from the control group: the event of invasive mechanical ventilation or death was reduced by 43% between steroid group and control group (19.3 % vs. 34.1 % respectively, p=0.001) and mortality was reduced by about 31% between steroid and usual care alone (15.8 % vs. 22.8 % respectively, p=0.011). Corticosteroids in selected COVID-19 patients may have a relevant impact on outcome, better profiling of the heterogeneity of this disease may be essential to guarantee the best treatment choices.
Articolo in rivista - Articolo scientifico
Covid19
English
Vergnano, B., Calcinati, S., Signori, D., Benini, A., Pozzi, M., Verga, L., et al. (2021). Steroids in severe COVID-19 patients: A retrospective analysis on the first pandemics in Lombardy. EMERGENCY CARE JOURNAL, 17(3) [10.4081/ecj.2021.9888].
Vergnano, B; Calcinati, S; Signori, D; Benini, A; Pozzi, M; Verga, L; Pizzagalli, J; Bonfanti, P; Bellani, G; Foti, G
File in questo prodotto:
File Dimensione Formato  
9888-Article Text-54812-1-10-20210921.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 711.18 kB
Formato Adobe PDF
711.18 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/327966
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
Social impact